Liver Fibrosis Resolution: From Molecular Mechanisms to Therapeutic Opportunities
Open accessThe DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Abstract
The liver is a critical system for metabolism in human beings, which plays an essential role in an abundance of physiological processes and is vulnerable to endogenous or exogenous injuries. After the damage to the liver, a type of aberrant wound healing response known as liver fibrosis may happen, which can result in an excessive accumulation of extracellular matrix (ECM) and then cause cirrhosis or hepatocellular carcinoma (HCC), seriously endangering human health and causing a great economic burden. However, few effective anti-fibrotic medications are clinically available to treat liver fibrosis. The most efficient approach to liver fibrosis prevention and treatment currently is to eliminate its causes, but this approach’s efficiency is too slow, or some causes cannot be fully eliminated, which causes liver fibrosis to worsen. In cases of advanced fibrosis, the only available treatment is liver transplantation. Therefore, new treatments or therapeutic agents need to be explored to stop the further development of early liver fibrosis or to reverse the fibrosis process to achieve liver fibrosis resolution. Understanding the mechanisms that lead to the development of liver fibrosis is necessary to find new therapeutic targets and drugs. The complex process of liver fibrosis is regulated by a variety of cells and cytokines, among which hepatic stellate cells (HSCs) are the essential cells, and their continued activation will lead to further progression of liver fibrosis. It has been found that inhibiting HSC activation, or inducing apoptosis, and inactivating activated hepatic stellate cells (aHSCs) can reverse fibrosis and thus achieve liver fibrosis regression. Hence, this review will concentrate on how HSCs become activated during liver fibrosis, including intercellular interactions and related signaling pathways, as well as targeting HSCs or liver fibrosis signaling pathways to achieve the resolution of liver fibrosis. Finally, new therapeutic compounds targeting liver fibrosis are summarized to provide more options for the therapy of liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, liver fibrosis is now recognized as a potentially reversible process, with resolution being closely linked to the reprogramming of macrophages towards restorative phenotypes characterized by enhanced efferocytosis, reduced pro-inflammatory signaling, and increased matrix degradation capacity.”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Resolution of fibrosis involves not only the degradation of ECM but also reprogramming of the immune microenvironment (87, 88).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909 · cited 1×
“HSC activation can be regulated by the Hippo pathway [65].”
BackgroundMechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
Heldin, C.-H., & Westermark, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1283 · Cited by 2,496 · cited 1×
“PDGF belongs to a group of growth factors whose physiological functions include controlling cell proliferation and migration and promoting the synthesis of vital components of the connective tissue matrix [23,61].”
BackgroundHepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485 · cited 1×
“Consequently, reducing the number of aHSCs, including inhibiting their proliferation or activation [7,24], promoting HSC apoptosis or autophagy [11,68,80], and deactivating the activated HSCs [76,77] to reverse liver fibrosis, may be an anti-fibrosis strategy [81].”
BackgroundMacrophages: master regulators of inflammation and fibrosis
Wynn, T., & Barron, L. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255354 · Cited by 1,392 · cited 1×
“Among them, hepatic macrophages (KCs), which are located within the lumen of the liver sinusoids [17], play crucial roles in liver fibrosis development [47].”
BackgroundLiver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061 · cited 1×
“The predominant macrophage populations in the initial stages of the damage are pro-inflammatory [46].”
BackgroundLiver sinusoidal endothelial cells: Physiology and role in liver diseases
Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., & Rautou, P.-E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.009 · Cited by 1,047 · cited 1×
“Although changing the phenotype of LSECs, this imbalance also helps to activate HSCs, which in turn encourages inflammation and liver fibrosis [43,44].”
BackgroundPathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894 · cited 1×
“Eliminating the chronic liver injury causes liver fibrosis to regress along with a decrease or disappearance of aHSCs [74].”
BackgroundTGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Dewidar, B., Meyer, C., Dooley, S., & Meindl-Beinker, A. N. (2019) · Cells · doi:10.3390/cells8111419 · Cited by 837
Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration
Ding, B.-S., Nolan, D. J., Butler, J. M., James, D., Babazadeh, A. O., Rosenwaks, Z., Mittal, V., Kobayashi, H., Shido, K., Lyden, D., et al. (2010) · Nature · doi:10.1038/nature09493 · Cited by 836 · cited 1×
“LSECs mostly exhibit anti-inflammatory, anti-fibrotic, and regeneration-promoting actions in healthy liver tissue [41].”
BackgroundMyofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201840109 · Cited by 805 · cited 4×
“Consequently, targeting the deactivation of aHSCs has become a novel and effective method for liver fibrosis resolution [76,97].”
BackgroundMethodInfluentialTGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis
Xu, F., Liu, C., Zhou, D., & Zhang, L. (2016) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415627681 · Cited by 756
Reactive oxygen and mechanisms of inflammatory liver injury: Present concepts
Jaeschke, H. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06592.x · Cited by 594 · cited 1×
“Inflammation brought on by persistent liver injury can be triggered by the release of ROS and other signals from damaged cells, which in turn activate inflammatory cells like macrophages, lymphocytes, and others [45].”
BackgroundKrenkel, O., Puengel, T., Govaere, O., Abdallah, A. T., Mossanen, J. C., Kohlhepp, M., Liepelt, A., Lefebvre, E., Luedde, T., Hellerbrand, C., et al. (2018) · Hepatology · doi:10.1002/hep.29544 · Cited by 557 · cited 1×
“The main ways to achieve liver fibrosis regression [3] are to eliminate the factors causing liver damage [70], reduce the number of aHSCs [71], inhibit the signal pathways linked to liver fibrosis [72], and promote the degradation of the ECM [73] (Figure 1).”
BackgroundThe good and the bad collagens of fibrosis – Their role in signaling and organ function
Karsdal, M. A., Nielsen, S. H., Leeming, D. J., Langholm, L. L., Nielsen, M. J., Manon-Jensen, T., Siebuhr, A., Gudmann, N. S., Rønnow, S., Sand, J. M., et al. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.014 · Cited by 509 · cited 1×
“The main ways to achieve liver fibrosis regression [3] are to eliminate the factors causing liver damage [70], reduce the number of aHSCs [71], inhibit the signal pathways linked to liver fibrosis [72], and promote the degradation of the ECM [73] (Figure 1).”
BackgroundLiver sinusoidal endothelial cells in hepatic fibrosis
DeLeve, L. D. (2015) · Hepatology · doi:10.1002/hep.27376 · Cited by 482 · cited 1×
“Studies have demonstrated that LSECs can maintain HSCs quiescence through a vascular endothelial growth factor (VEGF)-stimulated pathway [42].”
BackgroundPeroxisome proliferator-activated receptors and hepatic stellate cell activation
Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006577200 · Cited by 473
Liver fibrosis: Direct antifibrotic agents and targeted therapies
Schuppan, D., Ashfaq-Khan, M., Yang, A. T., & Kim, Y. O. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.04.006 · Cited by 435
Xie, G., Wang, X., Wang, L., Wang, L., Atkinson, R. D., Kanel, G. C., Gaarde, W. A., & DeLeve, L. D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.017 · Cited by 410 · cited 1×
“Although changing the phenotype of LSECs, this imbalance also helps to activate HSCs, which in turn encourages inflammation and liver fibrosis [43,44].”
BackgroundThe Hippo pathway effector YAP controls mouse hepatic stellate cell activation
Mannaerts, I., Leite, S. B., Verhulst, S., Claerhout, S., Eysackers, N., Thoen, L. F. R., Hoorens, A., Reynaert, H., Halder, G., & van Grunsven, L. A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.011 · Cited by 410
Iredale, J., & Campana, L. (2017) · Seminars in Liver Disease · doi:10.1055/s-0036-1597816 · Cited by 381 · cited 2×
“The resulting aHSCs are a crucial part of the fibrosis response that is driven by numerous pathways and is one of the primary effector cells in liver fibrosis [58].”
BackgroundArtesunate alleviates liver fibrosis by regulating ferroptosis signaling pathway
Kong, Z., Liu, R., & Cheng, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.030 · Cited by 360 · cited 1×
“HSCs’ aberrant activation and proliferation during the progression of liver fibrosis may accelerate the death of other healthy liver cells, leading to further deterioration of the disease [90,91].”
BackgroundJun, J.-I., & Lau, L. F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93563 · Cited by 345 · cited 1×
“The main ways to achieve liver fibrosis regression [3] are to eliminate the factors causing liver damage [70], reduce the number of aHSCs [71], inhibit the signal pathways linked to liver fibrosis [72], and promote the degradation of the ECM [73] (Figure 1).”
BackgroundHazra, S., Xiong, S., Wang, J., Rippe, R. A., Krishna, V., Chatterjee, K., & Tsukamoto, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310284200 · Cited by 320
Issa, R., Williams, E., Trim, N., Kendall, T., Arthur, M. J. P., Reichen, J., Benyon, R. C., & Iredale, J. P. (2001) · Gut · doi:10.1136/gut.48.4.548 · Cited by 319 · cited 2×
“Studies on animal models of liver injury induced by different methods have shown that reducing the number of HSCs by inducing apoptosis is directly related to the regression of fibrosis, suggesting that HSC apoptosis is also a major determinant for liver fibrosis regression [75,92].”
BackgroundAn, P., Wei, L.-L., Zhao, S., Sverdlov, D. Y., Vaid, K. A., Miyamoto, M., Kuramitsu, K., Lai, M., & Popov, Y. V. (2020) · Nature Communications · doi:10.1038/s41467-020-16092-0 · Cited by 319 · cited 1×
“HSCs’ aberrant activation and proliferation during the progression of liver fibrosis may accelerate the death of other healthy liver cells, leading to further deterioration of the disease [90,91].”
BackgroundWu, L., Zhang, Q., Mo, W., Feng, J., Li, S., Li, J., Liu, T., Xu, S., Wang, W., Lu, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09673-5 · Cited by 271
Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression
Caligiuri, A., Gentilini, A., Pastore, M., Gitto, S., & Marra, F. (2021) · Cells · doi:10.3390/cells10102759 · Cited by 270 · cited 7×
“Although the source of activated MFs may vary depending on the different etiologies, HSCs can be considered their main origin [3].”
BackgroundInfluentialCellular Mechanisms of Liver Fibrosis
Acharya, P., Chouhan, K., Weiskirchen, S., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671640 · Cited by 252 · cited 3×
“Moreover, it has been demonstrated that Hippo pathway elements, including YAP1 and the protein kinases macrophage stimulation 1 (MST1) and MST2, are essential for the initial activation of HSCs [67].”
BackgroundPDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics
Ying, H.-Z., Chen, Q., Zhang, W.-Y., Zhang, H.-H., Ma, Y., Zhang, S.-Z., Fang, J., & Yu, C.-H. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7641 · Cited by 238 · cited 1×
“Once these downstream components control the expression levels of pro-fibrosis target genes, liver fibrosis is facilitated [10,64].”
BackgroundThe cell biology of the hepatocyte: A membrane trafficking machine
Schulze, R. J., Schott, M. B., Casey, C. A., Tuma, P. L., & McNiven, M. A. (2019) · Journal of Cell Biology · doi:10.1083/jcb.201903090 · Cited by 236 · cited 1×
“Hepatocytes perform a variety of tasks in physiological environments, including detoxification and the release of bile, proteins, and lipids [37].”
BackgroundThe balancing act of the liver: tissue regeneration versus fibrosis
Cordero-Espinoza, L., & Huch, M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93562 · Cited by 219 · cited 1×
“The main ways to achieve liver fibrosis regression [3] are to eliminate the factors causing liver damage [70], reduce the number of aHSCs [71], inhibit the signal pathways linked to liver fibrosis [72], and promote the degradation of the ECM [73] (Figure 1).”
BackgroundKoda, Y., Teratani, T., Chu, P.-S., Hagihara, Y., Mikami, Y., Harada, Y., Tsujikawa, H., Miyamoto, K., Suzuki, T., Taniki, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24734-0 · Cited by 219 · cited 7×
“Hippo is a signaling mechanism that modulates the size of cells and organs.”
BackgroundInfluentialSelective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis
Haak, A. J., Kostallari, E., Sicard, D., Ligresti, G., Choi, K. M., Caporarello, N., Jones, D. L., Tan, Q., Meridew, J., Diaz Espinosa, A. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau6296 · Cited by 218
Osteopontin Takes Center Stage in Chronic Liver Disease
Song, Z., Chen, W., Athavale, D., Ge, X., Desert, R., Das, S., Han, H., & Nieto, N. (2021) · Hepatology · doi:10.1002/hep.31582 · Cited by 213
Hippo signalling in the liver: role in development, regeneration and disease
Russell, J. O., & Camargo, F. D. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00571-w · Cited by 207 · cited 2×
“Yes-associated protein 1 (YAP1), a Hippo pathway downstream effector, is essential for regulating HSC activation in response to chronic damage [53,66].”
BackgroundLiu, X., Xu, J., Rosenthal, S., Zhang, L.-J., McCubbin, R., Meshgin, N., Shang, L., Koyama, Y., Ma, H.-Y., Sharma, S., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.027 · Cited by 205 · cited 3×
“Consequently, targeting the deactivation of aHSCs has become a novel and effective method for liver fibrosis resolution [76,97].”
BackgroundMethodSTAT3: A key regulator in liver fibrosis
Zhao, J., Qi, Y.-F., & Yu, Y.-R. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2020.06.010 · Cited by 199 · cited 2×
“HSCs also perform a transdifferentiation process that changes them to a proliferative and contractile myofibroblast phenotype from a quiescent phenotype [13,36].”
BackgroundMu, M., Zuo, S., Wu, R.-M., Deng, K.-S., Lu, S., Zhu, J.-J., Zou, G.-L., Yang, J., Cheng, M.-L., & Zhao, X.-K. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s186726 · Cited by 186
Kocabayoglu, P., Lade, A., Lee, Y. A., Dragomir, A.-C., Sun, X., Fiel, M. I., Thung, S., Aloman, C., Soriano, P., Hoshida, Y., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.036 · Cited by 184 · cited 1×
“The activation of HSCs is then stimulated by PDGF using an autocrine pathway [62,63].”
MethodNon-canonical (non-SMAD2/3) TGF-β signaling in fibrosis: Mechanisms and targets
Finnson, K. W., Almadani, Y., & Philip, A. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.11.013 · Cited by 179 · cited 1×
“Both canonical (Smad) and non-canonical (non-Smad) pathways can be used by TGF-β to cause fibrosis [54].”
BackgroundAlcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in the cancer diseases
Jelski, W., & Szmitkowski, M. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.05.001 · Cited by 177 · cited 1×
“A metabolic enzyme called alcohol dehydrogenase (ADH) is mostly expressed in the liver, and ADHI is the classical liver ADH among these family members [84].”
BackgroundLiu, C., Tao, Q., Sun, M., Wu, J. Z., Yang, W., Jian, P., Peng, J., Hu, Y., Liu, C., & Liu, P. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.123 · Cited by 166 · cited 1×
“Additionally, the activation of KCs can boost HSCs’ nuclear factor kappa-B (NF-κB), which in turn encourages the release of pro-inflammatory cytokines [49].”
BackgroundIGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner
Nishizawa, H., Iguchi, G., Fukuoka, H., Takahashi, M., Suda, K., Bando, H., Matsumoto, R., Yoshida, K., Odake, Y., Ogawa, W., et al. (2016) · Scientific Reports · doi:10.1038/srep34605 · Cited by 164 · cited 1×
“Moreover, clinical and experimental studies have both demonstrated that the disappearance of aHSCs by apoptosis [75], inactivation into a quiescent-like state [76,77], or senescence [78] may lead to the regression of liver fibrosis.”
BackgroundZhang, J., Li, Y., Liu, Q., Huang, Y., Li, R., Wu, T., Zhang, Z., Zhou, J., Huang, H., Tang, Q., et al. (2021) · Hepatology · doi:10.1002/hep.31418 · Cited by 158 · cited 3×
“Additionally, the two primary downstream mediators are Smad2 and Smad3 [55,56].”
BackgroundNanoparticles for the treatment of liver fibrosis
Poilil Surendran, S., George Thomas, R., Moon, M.-J., & Jeong, Y. Y. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s145951 · Cited by 139
Bai, T., Lian, L., Wu, Y., Wan, Y., & Nan, J. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2012.12.020 · Cited by 128
Cross-talk between Notch and Hedgehog regulates hepatic stellate cell fate in mice
Xie, G., Karaca, G., Swiderska-Syn, M., Michelotti, G. A., Krüger, L., Chen, Y., Premont, R. T., Choi, S. S., & Diehl, A. M. (2013) · Hepatology · doi:10.1002/hep.26511 · Cited by 125
Bisht, S., Khan, M. A., Bekhit, M., Bai, H., Cornish, T. C., Mizuma, M., Rudek, M. A., Zhao, M., Maitra, A., Ray, B., et al. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.86 · Cited by 125
Nishikawa, K., Osawa, Y., & Kimura, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103103 · Cited by 125
Martí-Rodrigo, A., Alegre, F., Moragrega, Á. B., Garcia‐García, F., Martí‐Rodrigo, P., Fernández‐Iglesias, A., Gracia‐Sancho, J., Apostolova, N., Esplugues, J. V., & Blas‐García, A. (2019) · Gut · doi:10.1136/gutjnl-2019-318372 · Cited by 118
Ma, L., Wei, J., Zeng, Y., Liu, J., Xiao, E., Kang, Y., & Kang, Y. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2030428 · Cited by 109 · cited 1×
“CircDIDO1 (death-inducer obliterator 1) inhibits HSC activation by inhibiting the Akt pathway, and overexpression of circDIDO1 can induce cell cycle arrest and inhibit HSC proliferation and activation in the human HSC cell line LX-2 [89].”
BackgroundBansal, R., van Baarlen, J., Storm, G., & Prakash, J. (2015) · Scientific Reports · doi:10.1038/srep18272 · Cited by 107
Kupffer-derived matrix metalloproteinase-9 contributes to liver fibrosis resolution
Feng, M., Ding, J., Wang, M., Zhang, J., Zhu, X., & Guan, W. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.25589 · Cited by 106 · cited 2×
“Additionally, earlier research supported the belief that fibrosis was an unreversible process, but a growing number of clinical investigations have demonstrated that fibrosis will have regression at least partially when the underlying cause is eliminated [3,17,69].”
BackgroundYang, Y., Sun, M., Li, W., Liu, C., Jiang, Z., Gu, P., Li, J., Wang, W., You, R., Ba, Q., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.410 · Cited by 102
Platelet TGF-β1 deficiency decreases liver fibrosis in a mouse model of liver injury
Ghafoory, S., Varshney, R., Robison, T., Kouzbari, K., Woolington, S., Murphy, B., Xia, L., & Ahamed, J. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017010868 · Cited by 96 · cited 3×
“TGF-β, a crucial pro-fibrotic cytokine in the liver [50,51], includes TGF-β1, TGF-β2, and TGF-β3, among which TGF-β1 is the most potent of these proteins and the main regulator of chronic liver disease, increasing the illness’s progression from early liver damage to inflammation, fibrosis, and cirrhosis, even HCC [52,…”
BackgroundWang, Y., Tu, K., Liu, D., Guo, L., Chen, Y., Li, Q., Maiers, J. L., Liu, Z., Shah, V. H., Dou, C., et al. (2019) · Hepatology · doi:10.1002/hep.30668 · Cited by 93 · cited 3×
“Additionally, the two primary downstream mediators are Smad2 and Smad3 [55,56].”
BackgroundPerumal, N., Perumal, M. K., Devaraj, H., & NiranjaliDevaraj, S. (2017) · Biochimie · doi:10.1016/j.biochi.2017.05.017 · Cited by 92 · cited 7×
“[53] Downregulating TGF-β signaling Attenuating fibrillar collagen deposition Preventing HSC activation”
BackgroundInfluentialIn vitro reversion of activated primary human hepatic stellate cells
El Taghdouini, A., Najimi, M., Sancho-Bru, P., Sokal, E., & van Grunsven, L. A. (2015) · Fibrogenesis & Tissue Repair · doi:10.1186/s13069-015-0031-z · Cited by 91 · cited 3×
“Moreover, clinical and experimental studies have both demonstrated that the disappearance of aHSCs by apoptosis [75], inactivation into a quiescent-like state [76,77], or senescence [78] may lead to the regression of liver fibrosis.”
BackgroundAstaxanthin in Liver Health and Disease: A Potential Therapeutic Agent
Li, J., Guo, C., & Wu, J. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s230749 · Cited by 91
Nakano, Y., Kamiya, A., Sumiyoshi, H., Tsuruya, K., Kagawa, T., & Inagaki, Y. (2020) · Hepatology · doi:10.1002/hep.30965 · Cited by 86
Son, M. K., Ryu, Y.-L., Jung, K. H., Lee, H., Lee, H. S., YAN, H. H., Park, H. J., Ryu, J., Suh, J., Hong, S., et al. (2013) · Scientific Reports · doi:10.1038/srep03470 · Cited by 84
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis: Updated
Dewidar, B., Soukupová, J., Fabregat, I., & Dooley, S. (2015) · Current Pathobiology Reports · doi:10.1007/s40139-015-0089-8 · Cited by 81
Li, J., Zeng, C., Zheng, B., Liu, C., Tang, M., Jiang, Y., Chang, Y., Song, W., Wang, Y., & Yang, C. (2018) · Clinical Science · doi:10.1042/cs20180177 · Cited by 81 · cited 2×
“Sci. 2023, 24, 9671 7 of 24 primary cause of chronic inflammation might cause severe liver fibrosis brought on by chronic HBV and hepatitis C virus (HCV) infection to regress [13].”
BackgroundWang, M., Zhang, M., Fu, L., Lin, J., Zhou, X., Zhou, P., Huang, P., Hu, H., & Han, Y. (2020) · Theranostics · doi:10.7150/thno.37301 · Cited by 81
Lee, J., Byun, J., Shim, G., & Oh, Y.-K. (2022) · Nature Communications · doi:10.1038/s41467-022-29186-8 · Cited by 79
Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis
Garbuzenko, D. V. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i12.3662 · Cited by 78 · cited 1×
“In the process of developing liver fibrosis, HSCs are crucial [5,30].”
BackgroundKaempferol attenuates liver fibrosis by inhibiting activin receptor–like kinase 5
Xu, T., HUANG, S. H., Huang, Q., Ming, Z., Wang, M., Li, R., & Yin-nong, Z. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14528 · Cited by 77
The Role of Autophagy and NLRP3 Inflammasome in Liver Fibrosis
Tao, Y., Wang, N., Qiu, T., & Sun, X. (2020) · BioMed Research International · doi:10.1155/2020/7269150 · Cited by 77
Zhang, J., Yang, A., Wu, Y. C., Guan, W., Xiong, B., Peng, X., Wei, X., Chen, G., & Liu, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.117 · Cited by 76
Basso, B. D. S., Haute, G. V., Ortega‐Ribera, M., Luft, C., Antunes, G. L., Bastos, M. S., Carlessi, L. P., Levorse, V. G. S., Cassel, E., Donadio, M. V. F., et al. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114433 · Cited by 76 · cited 7×
“Peroxisome proliferator-activated receptor-γ (PPAR-γ), which is a major regulator of the adipogenesis process, has been found to associate with the activation of HSCs [77].”
BackgroundMethodInfluentialLiu, Z., Zhu, P., Zhang, L., Xiong, B., Tao, J., Guan, W., Li, C., Chen, G., Gu, J., Duanmu, J., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.156 · Cited by 74 · cited 4×
“Natural compounds have gained prominence globally in recent years as one of the most significant sources of anti-fibrosis medications due to their affordability and accessibility [8,57].”
BackgroundInfluentialIntegrins as a drug target in liver fibrosis
Rahman, S. R., Roper, J. A., Grove, J. I., Aithal, G. P., Pun, K. T., & Bennett, A. J. (2022) · Liver International · doi:10.1111/liv.15157 · Cited by 74 · cited 6×
“The most potent fibrogenic cytokine, TGF-β, has an influence on all stages of disease progression, from primary liver injury to fibrosis and cirrhosis [14,109].”
BackgroundInfluentialNanotechnology in Drug Delivery for Liver Fibrosis
Gu, L., Zhang, F., Wu, J., & Zhuge, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.804396 · Cited by 73 · cited 3×
“Currently, the only effective treatment for advanced liver disease is liver transplantation [15,18], but it has its limitations.”
BackgroundWang, N., Li, X., Zhong, Z., Qiu, Y., Liu, S., Wu, H., Tang, X., Chen, C., Fu, Y., Chen, Q., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01138-2 · Cited by 73
Antibacterial, Antiurease, and Antioxidant Activities of Some Arylidene Barbiturates
Sökmen, B. B., Uğraş, S., Sarikaya, H. Y., Uğraş, H. İ., & Yanardağ, R. (2013) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-013-0486-6 · Cited by 72
Li, X., Peng, J., Sun, Z., Tian, H., Duan, X., Liu, L., Ma, X., Feng, Q., Liu, P., & Hu, Y. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.35 · Cited by 72
Molecular Mechanisms and Potential New Therapeutic Drugs for Liver Fibrosis
Wang, F.-D., Zhou, J., & Chen, E.-Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.787748 · Cited by 71
Old wine in new bottles: Kaempferol is a promising agent for treating the trilogy of liver diseases
Xiao, X., Hu, Q., Deng, X., Shi, K., Zhang, W., Jiang, Y., Ma, X., Zeng, J., & Wang, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106005 · Cited by 70
Wang, L., Wang, Y., & Quan, J. (2020) · Human Cell · doi:10.1007/s13577-020-00371-5 · Cited by 65 · cited 1×
“In addition, it has been found that exosomes, a type of extracellular vesicles (EVs), from various cell sources can also stimulate HSCs and play an important role in the process of liver fibrosis [32,33].”
BackgroundDu, Y., Lai, L., Zhang, H., Zhong, F., Cheng, H., Qian, B., Tan, P., Xia, X., & Fu, W. (2020) · Food & Function · doi:10.1039/d0fo00724b · Cited by 64
Wu, J., Xue, X., Fan, G., Gu, Y., Zhou, F., Zheng, Q., Liu, R., Li, Y., Ma, B.-N., Li, S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.754976 · Cited by 64 · cited 4×
“Ferulic acid (FA) CCl4-induced fibrotic models in male C57BL/6J mice Inhibiting hepatic oxidative stress, macrophage activation, and HSC activation [25,120] CCl4-induced liver fibrosis in male Wistar rats Through PTP1B and AMPK signaling pathways.”
BackgroundInfluentialLuo, X., Xu, Z.-X., Wu, J.-C., Luo, S.-Z., & Xu, M.-Y. (2021) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2021.10.022 · Cited by 64 · cited 1×
“Lipotoxic hepatocyte-derived exosomal miR-27a was found to promote the development of liver fibrosis in metabolically associated fatty liver disease (MAFLD) by enhancing HSC proliferation and activation and inhibiting aHSC autophagy [40].”
BackgroundNatural Sulfur-Containing Compounds: An Alternative Therapeutic Strategy against Liver Fibrosis
Milito, A., Brancaccio, M., D’Argenio, G., & Castellano, I. (2019) · Cells · doi:10.3390/cells8111356 · Cited by 63 · cited 2×
“In addition to encouraging the recruitment of circulating inflammatory cells into the liver, ROS can encourage KCs to release pro-fibrotic mediators, which in turn activate HSCs [10].”
BackgroundGe, M., Liu, H., Zhang, N., Niu, W., Lu, Z.-N., Bao, Y., Huang, R., Yu, D., Shao, R., & He, H. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14873 · Cited by 62
HMGB1: An overview of its roles in the pathogenesis of liver disease
Ni, Y.-A., Chen, H., Nie, H., Zheng, B., & Gong, Q. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr0121-277r · Cited by 60 · cited 1×
“High-mobility group box-1 (HMGB1), a DNA-binding non-histone nuclear protein, is typically produced in eukaryotic cells and is one of the most researched DAMPs in liver disease [38].”
BackgroundGATA4 induces liver fibrosis regression by deactivating hepatic stellate cells
Arroyo, N., Villamayor, L., Díaz, I., Carmona, R., Ramos-Rodríguez, M., Muñoz-Chápuli, R., Pasquali, L., Toscano, M. G., Martín, F., Cano, D. A., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150059 · Cited by 60 · cited 2×
“After that, aHSCs can express α-SMA and produce ECM components like collagen and laminin [83].”
BackgroundZhang, Q., Luo, P., Zheng, L., Chen, J., Zhang, J., Tang, H., Liu, D., He, X., Shi, Q., Gu, L., et al. (2022) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2022.06.001 · Cited by 60 · cited 4×
“[19] Resulting in the accumulation of cellular ROS Inducing apoptosis in activated HSCs”
BackgroundInfluentialActivation of Platelet-Derived Growth Factor Receptor Alpha Contributes to Liver Fibrosis
Hayes, B. J., Riehle, K. J., Shimizu-Albergine, M., Bauer, R. L., Hudkins, K. L., Johansson, F., Yeh, M. M., Mahoney, W. M., Yeung, R. S., & Campbell, J. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092925 · Cited by 59 · cited 1×
“The activation of HSCs is then stimulated by PDGF using an autocrine pathway [62,63].”
MethodSalunkhe, S. A., Chitkara, D., Mahato, R. I., & Mittal, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.003 · Cited by 57
Zhao, H., Wang, Z., Tang, F., Zhao, Y., Feng, D., Li, Y., Hu, Y. W., Wang, C., Zhou, J., Tian, X., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.10.013 · Cited by 56 · cited 3×
“Thus quiescent hepatic stellate cells (qHSCs) activation and subsequent conversion into MFs are essential occurrences in the pathogenesis of liver fibrosis [7,26,28].”
BackgroundXu, T., Ni, M.-M., Xingli, Li, X., Meng, X., Huang, C., & Li, J. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.11.010 · Cited by 54 · cited 1×
“Therefore, the reversal of liver fibrosis can be achieved by accelerating the death of aHSCs and reducing the total number of aHSCs [93,94].”
BackgroundNatural Products that Target the NLRP3 Inflammasome to Treat Fibrosis
Ding, N., Wei, B., Fu, X., Wang, C., & Wu, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.591393 · Cited by 54 · cited 3×
“, released by activated macrophages, platelets, and damaged hepatocytes, activate the qHSCs when the liver is injured [23,27].”
BackgroundDahuang Zhechong pill attenuates CCl4‐induced rat liver fibrosis via the PI3K‐Akt signaling pathway
Gong, Z., Lin, J., Zheng, J., Wei, L., Liu, L., Peng, Y., Liang, W., & Hu, G. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29378 · Cited by 53
Liu, Y., Zheng, Y., Yang, Y., Liu, K., Wu, J., Gao, P., & Zhang, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133297 · Cited by 53 · cited 3×
“Therefore, exosomes can also be used as delivery carriers for the treatment of hepatic fibrosis [34].”
BackgroundNovel Therapeutic Targets in Liver Fibrosis
Zhang, J., Liu, Q., He, J., & Li, Y. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.766855 · Cited by 51 · cited 10×
“MFs, which secrete matrix proteins and are the primary cause of liver fibrogenesis, are mostly derived from activated hepatic stellate cells (aHSCs) [6].”
BackgroundInfluentialYoon, Y.-C., Fang, Z., Lee, J. E., Park, J. H., Ryu, J.-K., Jung, K. H., & Hong, S.-S. (2020) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2020.016 · Cited by 46
Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis
Peng, W., Cheng, S., Bao, Z., Wang, Y., Zhou, W., Wang, J., Yang, Q., Chen, C., & Wang, W. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111342 · Cited by 45 · cited 14×
“However, the biodegradability of inorganic NPs in vivo is poor, and the leftover NPs that accumulate there can harm the liver.”
BackgroundInfluentialZhang, H., Chen, Q., Dahan, A., Xue, J., Wei, L., Tan, W., & Zhang, G. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.05.041 · Cited by 44 · cited 4×
“Additionally, various etiological factors can lead to liver fibrosis, such as viral infections, alcohol, metabolic diseases, biliary diseases, hepatic toxins [9], autoimmune disease [5], and prolonged use of some medications, including methotrexate, methyldopa, chlorpromazine, tolbutamide, etc.”
BackgroundInfluentialZhang, S., Wang, Z., Zhu, J., Xu, T., Zhao, Y., Zhao, H., Tang, F., Li, Z., Zhou, J., Gao, D., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00976 · Cited by 43 · cited 7×
“Thus quiescent hepatic stellate cells (qHSCs) activation and subsequent conversion into MFs are essential occurrences in the pathogenesis of liver fibrosis [7,26,28].”
BackgroundInfluentialLee, S. W., Kim, S. M., Hur, W., Kang, B.-Y., Lee, H. L., Nam, H., Yoo, S. H., Sung, P. S., Kwon, J. H., Jang, J. W., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261067 · Cited by 43 · cited 2×
“In a mouse model of liver fibrosis, TDF leads to aHSC apoptosis by downregulating the PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway and ultimately improving liver fibrosis [96].”
BackgroundSong, Z., Liu, X., Zhang, W., Luo, Y., Xiao, H., Liu, Y., Dai, G., Hong, J., & Li, A. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03366-y · Cited by 43
Zheng, H., Li, S., Ma, L., Cheng, L., Deng, C., Chen, Z., Xie, C., Xiang, M., Jiang, W., & Chen, L. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.03.033 · Cited by 41
Tan, S., Liu, H., Ke, B., Jiang, J., & Wu, B. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15010 · Cited by 41 · cited 3×
“JD5037 CCl4-induced liver fibrosis in male mice Blocking the CB1 receptor/β-arrestin1/Akt signaling pathway [79] BDL-induced liver fibrosis in male mice Blocking the activation of HSCs”
BackgroundInfluentialLu, Z.-N., Niu, W., Zhang, N., Ge, M., Bao, Y., Ren, Y., Guo, X., & He, H. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00754-w · Cited by 41
The effect and mechanisms of Fuzheng Huayu formula against chronic liver diseases
Chen, J., Hu, Y., Chen, L., Liu, W., Mu, Y., & Liu, P. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108846 · Cited by 40
CCN2/CTGF promotes liver fibrosis through crosstalk with the Slit2/Robo signaling
Pi, L., Sun, C., Jn‐Simon, N., Basha, S., Thomas, H., Figueroa, V., Zarrinpar, A., Cao, Q., & Petersen, B. E. (2022) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-022-00713-y · Cited by 38 · cited 1×
“It has been found that exosomal cellular communication network factor 2 (CCN2), derived from HSCs, contains connective tissue growth factors that promote the development of liver fibrosis and can amplify or attenuate fiber formation signals by binding to other exosomal components [35].”
BackgroundThe versatility of macrophage heterogeneity in liver fibrosis
Gao, C.-C., Bai, J., Han, H., & Qin, H.-Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968879 · Cited by 37 · cited 3×
“Liver fibrosis, which results from an inappropriate response to liver injury’s wound-healing process, is a pathological condition [4,5], and the main pathological characteristics are the excessive accumulation of extracellular matrix (ECM) proteins and the loss of the normal structure of the liver tissue [6–8].”
BackgroundGong, J., Yang, F., Yang, Q., Tang, X., Shu, F., Xu, L., Wang, Z., & Yang, L. (2019) · Journal of Natural Medicines · doi:10.1007/s11418-019-01334-3 · Cited by 36
Zhao, Y., Wei, S., Niu, M., Wang, J., Wang, J., Su, H., Luo, S., Zhang, X., Guo, Y., Liu, L., et al. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s96964 · Cited by 35
Kindlin-2 regulates hepatic stellate cells activation and liver fibrogenesis
Yu, J., Hu, Y., Gao, Y., Li, Q., Zeng, Z., Li, Y., & Chen, H. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0095-9 · Cited by 35
Wei, Z., Xue, Y., Xue, Y., Cheng, J., Lv, G., Chu, L., Ma, Z., & Guan, S. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.05.006 · Cited by 35
Gonzalez, S. A., Fiel, M. I., Sauk, J. J., Canchis, P. W., Liu, R.-C., Chiriboga, L. A., Yee, H. T., Jacobson, I. M., & Talal, A. H. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2008.01052.x · Cited by 34 · cited 2×
“Studies on animal models of liver injury induced by different methods have shown that reducing the number of HSCs by inducing apoptosis is directly related to the regression of fibrosis, suggesting that HSC apoptosis is also a major determinant for liver fibrosis regression [75,92].”
BackgroundTherapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis
Kaftanovskaya, E. M., Ng, H. H., Soula, M., Rivas, B. L., Myhr, C. B., Ho, B. A., Cervantes, B., Shupe, T. D., Devarasetty, M., Hu, X., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201901046r · Cited by 34 · cited 5×
“Consequently, it is necessary to develop more effective therapies to delay fibrosis progression or promote regression of liver fibrosis, which can help prevent the advancement of cirrhosis or cancer [12,69].”
BackgroundInfluentialMiao, Y., Wu, Y., Jin, Y.-J., Lei, M., Nan, J., & Wu, X. Z. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.108945 · Cited by 34 · cited 5×
“Excessive production of ROS can result in oxidative stress, which promotes a sustained inflammatory response as well as HSC activation and proliferation, which then leads to the appearance and growth of liver fibrosis [68].”
BackgroundInfluentialSB431542-Loaded Liposomes Alleviate Liver Fibrosis by Suppressing TGF-β Signaling
Zhang, J., Li, R., Liu, Q., Zhou, J., Huang, H., Huang, Y., Zhang, Z., Wu, T., Tang, Q., Huang, C., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00633 · Cited by 34
Mo, C., Xie, S., Zeng, T., Lai, Y., Huang, S., Zhou, C., Yan, W., Huang, S., Gao, L., & Lv, Z. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153524 · Cited by 34
Zhu, X., Ye, S., Yu, D., Zhang, Y., Li, J., Zhang, M., Leng, Y., Yang, T., Luo, J., Chen, X., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15490 · Cited by 34
Tang, M., Guo, C., Sun, M., Zhou, H., Peng, X., Dai, J., Ding, Q., Wang, Y., & Yang, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.882243 · Cited by 33
Kong, L., Li, H., Du, Y.-J., PEI, F.-H., Hu, Y., Zhao, L.-L., & Chen, J. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6325 · Cited by 32
Zhang, Z., Mu, Y., Zhang, J., Zhou, Y., Cattaneo, P., Veevers, J., Peter, A. K., Manso, A. M., Knowlton, K. U., Zhou, X., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038383 · Cited by 32 · cited 1×
“For instance, kindlin-2 overexpression was related positively to the TGF-β signaling pathway, while activated TGF-β could promote kindlin-2 expression through the p38 and MAPK signaling pathways [59,60].”
BackgroundFu, Y., Xiao, Z., Tian, X., Liu, W., Zhou, X., Yang, T., Hu, Y., Zhou, X., Fang, J., Gao, S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671152 · Cited by 32
Control of Tissue Fibrosis by 5-Methoxytryptophan, an Innate Anti-Inflammatory Metabolite
Wu, K. K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.759199 · Cited by 31
Zhou, G., Li, C., Zhang, R., Zhan, Y., Lin, L., Lang, Z., Tao, Q., & Zheng, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881855 · Cited by 30
Gomisin D alleviates liver fibrosis through targeting PDGFRβ in hepatic stellate cells
Wang, R., Liu, F., Chen, P., Li, S., Gu, Y., Wang, L., Chen, C., & Yuan, Y. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123639 · Cited by 30 · cited 2×
“[82] Promoting HSC apoptosis Regulating the PDGF-BB/PDGFRβ signaling pathway”
BackgroundEndostar, a novel human recombinant endostatin, attenuates liver fibrosis in CCl 4 -induced mice
Chen, J., Liu, D.-G., Yang, G., Kong, L., Du, Y.-J., Wang, H., Li, F.-D., Pei, F., Song, J.-T., Fan, Y., et al. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214532595 · Cited by 29
Reversal of established liver fibrosis by IC-2-engineered mesenchymal stem cell sheets
Itaba, N., Kono, Y., Watanabe, K., Yokobata, T., Oka, H., Osaki, M., Kakuta, H., Morimoto, M., & Shiota, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-43298-0 · Cited by 29 · cited 1×
“Currently, the only effective treatment for advanced liver disease is liver transplantation [15,18], but it has its limitations.”
BackgroundLiao, Y., Hsu, S., Chien, C.-Y., Wang, Y.-H., Hsu, M.-H., & Suk, F. (2020) · Molecules · doi:10.3390/molecules25122856 · Cited by 29
Wang, Y.-H., Suk, F., Liu, C.-L., Chen, T.-L., Twu, Y., Hsu, M.-H., & Liao, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00388 · Cited by 28
Tong, M., Zheng, Q. Y., Liu, M., Chen, L., Lin, Y., Tang, S., & Zhu, Y. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1897241 · Cited by 28
Zhang, Y., Hua, L., Lin, C., Yuan, M., Xu, W., Anand Raj, D., Venkidasamy, B., Céspedes, C. L., Nile, S. H., Yan, G., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.937484 · Cited by 28 · cited 2×
“Pien-Tze-Huang (PZH) CCl4-induced liver fibrosis in male SD rats Autophagy and TGF-β1/Smad2 signaling pathways [80] Inhibiting HSC activation and diminishing fibrogenesis”
BackgroundA review of the effect of exosomes from different cells on liver fibrosis
Hu, X., Ge, Q.-L., Zhang, Y., Li, B., Cheng, E., Wang, Y.-H., & Huang, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114415 · Cited by 27 · cited 2×
“In addition, it has been found that exosomes, a type of extracellular vesicles (EVs), from various cell sources can also stimulate HSCs and play an important role in the process of liver fibrosis [32,33].”
BackgroundAlbumin mediates PPAR-γ or C/EBP-α-induced phenotypic changes in pancreatic stellate cells
Kim, N., Choi, S., Lim, C., Lee, H. S., & Oh, J. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.11.112 · Cited by 26 · cited 1×
“PPAR-γ levels are noticeably reduced during HSC activation [98], and overexpression of PPAR-γ in aHSCs induces a transition to a quieter phenotype [99,100].”
BackgroundZheng, M., Li, Y., Wang, G., Jin, J., Wang, Y., Wang, T.-M., Yang, L., Liu, S., Wu, J., Wang, Z.-T., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108701 · Cited by 26 · cited 6×
“Consequently, it is necessary to develop more effective therapies to delay fibrosis progression or promote regression of liver fibrosis, which can help prevent the advancement of cirrhosis or cancer [12,69].”
BackgroundInfluentialLin, X., Wei, Y., Li, Y., Xiong, Y., Fang, B., Li, C., Huang, Q., Huang, R., & Wei, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.801982 · Cited by 26
Wei, M., Zhang, Y., Zhang, H., Huang, Z., Miao, H., Zhang, T., Lü, B., & Ji, L. (2022) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2022.130202 · Cited by 26 · cited 1×
“HSCs are a unique group of pre-hepatic cells that are situated in the Disse space next to sinusoidal endothelial cells and hepatocytes [29].”
BackgroundCao, F., Zhang, Y., Li, W., Shimizu, K., Xie, H., & Zhang, C. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2017.12.023 · Cited by 25
Li, Z., Wang, Z., Dong, F., Shi, W., Dai, W., Zhao, J., Li, Q., Fang, Z.-E., Ren, L., Liu, T., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.745561 · Cited by 25
Hou, J., Tian, J., Jiang, W., Gao, Y., & Fu, F. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.019 · Cited by 24 · cited 4×
“TGF-β, a crucial pro-fibrotic cytokine in the liver [50,51], includes TGF-β1, TGF-β2, and TGF-β3, among which TGF-β1 is the most potent of these proteins and the main regulator of chronic liver disease, increasing the illness’s progression from early liver damage to inflammation, fibrosis, and cirrhosis, even HCC [52,…”
BackgroundInfluentialKarimi, J., Mohammadalipour, A., Sheikh, N., Khodadadi, I., Hashemnia, M., Goudarzi, F., Khanjarsim, V., Solgi, G., Hajilooi, M., Bahabadi, M., et al. (2018) · Drug and Chemical Toxicology · doi:10.1080/01480545.2018.1504960 · Cited by 24 · cited 2×
“Thus quiescent hepatic stellate cells (qHSCs) activation and subsequent conversion into MFs are essential occurrences in the pathogenesis of liver fibrosis [7,26,28].”
BackgroundLiu, H., Dai, L., Wang, M., Feng, F., & Xiao, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.684857 · Cited by 23 · cited 3×
“ADHI might encourage the proliferation, motility, adhesion, and invasion of HSC-T6 cells, a rat HSC line.”
BackgroundKodai, S., Takemura, S., Kubo, S., Azuma, H., & Minamiyama, Y. (2015) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.14-108 · Cited by 22
Metabolic mechanisms of Fuzheng-Huayu formula against liver fibrosis in rats
Hu, X., Song, Y., Wu, R., Cai, F., Zhang, Y., Peng, J., Hu, Y., & Su, S.-B. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.111888 · Cited by 22
Thymus fontanesii attenuates CCl4-induced oxidative stress and inflammation in mild liver fibrosis
Abdelghffar, E. A. R., Obaid, W. A., Alamoudi, M. O., Mohammedsaleh, Z. M., Annaz, H., Abdelfattah, M. A. O., & Sobeh, M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112738 · Cited by 22 · cited 1×
“This causes HSC activation and exacerbates liver fibrosis [6,13,48].”
BackgroundChen, K., Guo, W., Li, R., Han, Y., Gao, Q., & Wang, S. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154349 · Cited by 22
Higher Activity of Alcohol Dehydrogenase Is Correlated with Hepatic Fibrogenesis
Gao, N., Li, J., Li, M.-R., Qi, B., Wang, Z., Wang, G.-J., Gao, J., & Qiao, H. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.249425 · Cited by 20 · cited 1×
“Research [85] has shown that the activity of ADHI in human fibrotic liver is significantly higher than that in normal liver.”
BackgroundOkimoto, S., Kuroda, S., Tashiro, H., Kobayashi, T., Taogoshi, T., Matsuo, H., & Ohdan, H. (2019) · Hepatology Research · doi:10.1111/hepr.13317 · Cited by 19
Bestion, E., Jílková, Z. M., Mège, J., Novello, M., Kurma, K., Pour, S. T. A., Lalmanach, G., Vanderlynden, L., Fizanne, L., Bassissi, F., et al. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320942042 · Cited by 18
N-n-Butyl haloperidol iodide ameliorates liver fibrosis and hepatic stellate cell activation in mice
Shen, D., He, C., Cai, B., Cai, W.-F., Wang, B., Zhu, Q., Wu, Y.-B., Liu, M., Chen, R., Gao, F., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00630-7 · Cited by 18
Li, W., Zhang, Y., Yu, X., Wang, Z., Yin, M., Zhao, Z., & Li, Y. (2018) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_470_17 · Cited by 17 · cited 3×
“Pokeweed antiviral protein (PAP) CCl4-induced liver fibrosis in male C57/BL6 mice Inhibition of glycolysis through regulation of the Wnt/JNK pathway [24] Suppressing HSC activation”
BackgroundLi, W., Chen, J. Y., Sun, C., Sparks, R. P., Pantano, L., Rahman, R., Moran, S. P., Pondick, J. V., Kirchner, R., Wrobel, D., et al. (2022) · eLife · doi:10.7554/elife.74513 · Cited by 17
Kumar, A., Archoo, S., Singh, C. P., Naikoo, S. H., Singh, B., Kaur, S., & Abdullah, S. T. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128984 · Cited by 17
Ke, C., Gao, J., Tu, J., Wang, Y., Xiao, Y., Wu, Y. S., Liu, Y., & Zhou, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.930785 · Cited by 17
Zhang, Y., Cai, B., Li, Y., Xu, Y. J., Wang, Y., Zheng, L., Zheng, X., Yin, L., Chen, G., Wang, Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1098463 · Cited by 17
Nokkeaw, A., Thamjamrassri, P., Tangkijvanich, P., & Ariyachet, C. (2023) · Cells · doi:10.3390/cells12030378 · Cited by 16
Jiao, W., Bai, M., Yin, H., Liu, J., Sun, J., Su, X., Zeng, H., & Wen, J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.690170 · Cited by 13
Antibacterial activity of 18β-glycyrrhetinic acid against Neisseria gonorrhoeae in vitro
Zhao, Y., & Su, X. (2023) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2023.101427 · Cited by 13
Recent advances in the role of exosomes in liver fibrosis
Shen, J., Cao, J., Chen, M., & Zhang, Y. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16203 · Cited by 13
Raj, D., Sharma, V., Upadhyaya, A., Kumar, N., Joshi, R., Acharya, V., Kumar, D., & Patial, V. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114741 · Cited by 11 · cited 2×
“Additionally, various etiological factors can lead to liver fibrosis, such as viral infections, alcohol, metabolic diseases, biliary diseases, hepatic toxins [9], autoimmune disease [5], and prolonged use of some medications, including methotrexate, methyldopa, chlorpromazine, tolbutamide, etc.”
BackgroundHepato-protective role of itraconazole mediated cytochrome p450 pathway inhibition in liver fibrosis
Hadi, F., Awan, S. J., Tayyeb, A., Maqbool, T., Shehzadi, S., Malik, S., Kausar, H., & Malik, A. (2020) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps.2020.33.6.sup.2751-2758.1 · Cited by 11
Hadi, F., Awan, S. J., Tayyeb, A., Maqbool, T., Shehzadi, S., Malik, S., Kausar, H., & Malik, A. (2020) · PubMed · Cited by 9
Effect of ADHI on hepatic stellate cell activation and liver fibrosis in mice
Zhao, T., Han, Z., Zhang, J., Ding, Y., Chen, J., Qiao, H., & Gao, N. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.02.008 · Cited by 8 · cited 4×
“ADHI might encourage the proliferation, motility, adhesion, and invasion of HSC-T6 cells, a rat HSC line.”
BackgroundInfluentialMeng, H., Jiang, L., Jia, P., Niu, R., Bu, F., Zhu, Y. Y., Pan, X., Li, J., Liu, J., Zhang, Y., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115451 · Cited by 8 · cited 1×
“The inhibition of circASPH, which is derived from the aspartate β-hydroxylase (ASPH) gene locus, can suppress the activation and proliferation of HSCs, while its upregulation promoted the occurrence of these events in a CCl4-induced mouse model of liver fibrosis [88].”
BackgroundSong, Y. R., Jang, M., Jang, B., Bae, S.-J., Bak, S. B., Lee, S. M., Yun, U.-J., Lee, J., Park, S. M., Jung, D. H., et al. (2022) · Molecular & Cellular Toxicology · doi:10.1007/s13273-021-00196-9 · Cited by 4
Wu, B., Huang, L., Wang, Y., Zeng, L., Lin, Y., Li, J., Wang, S., Zhang, G., & An, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1043022 · Cited by 3
Antiliver Fibrosis Formula of Fuzheng Huayu Alleviates Inflammatory Response
Chang, Q.-Q., Pan, Y., Yang, J., Li, R.-S., Yuan, C.-L., Liao, Y.-F., Zhang, D., & Liu, C. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/5752803 · Cited by 2
Cited by
Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy
Seyhan, D., Allaire, M., Fu, Y., Conti, F., Wang, X. W., Gao, B., & Lafdil, F. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01308-4 · Cited by 164
“In contrast to its advanced cirrhotic state, liver fi brosis is reversible [28, 29].”
Yin, Y., Feng, W., Chen, J., Chen, X., Wang, G., Wang, S., Xu, X., Nie, Y., Fan, D., Wu, K., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00539-x · Cited by 137
“Chronic inflammation due to persistent liver damage can induce fibrosis by disrupting the normal healing response [18].”
BackgroundLiver Fibrosis Leading to Cirrhosis: Basic Mechanisms and Clinical Perspectives
Somnay, K., Wadgaonkar, P., Sridhar, N., Roshni, P., Rao, N., & Wadgaonkar, R. (2024) · Biomedicines · doi:10.3390/biomedicines12102229 · Cited by 70
Kidney Fibrosis: Fundamental Questions, Challenges, and Perspectives
Liu, Y. (2024) · Integrative Medicine in Nephrology and Andrology · doi:10.1097/imna-d-24-00027 · Cited by 74
Liu, W., Zhang, L., Wei, X., Xu, Y., Fang, Q., Qi, S., Chen, J., Wang, C., Wang, S., Qin, L., et al. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.121659 · Cited by 52
Metadata
- Authors
- Pei, Q., Yi, Q., & Tang, L.
- Affiliations
- Chongqing University (CN)
- Southwest Medical University (CN)
- Corresponding author
- Yi, Qian
- Tang, Liling
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-06-02
- Volume
- 24
- Issue
- 11
- Pages
- 9671
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10253436
- OpenAlex
- W4379230272
- Cited by
- 121
- References
- 167
- Citations by year
- 2026: 37 · 2025: 43 · 2024: 36 · 2023: 5
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (32271363, 2021-JYJ-71, 2022NSFSC1368)
- Luzhou Science and Technology Program (32271363, 2021-JYJ-71, 2022NSFSC1368)
- Sichuan Science and Technology Program (32271363, 2021-JYJ-71, 2022NSFSC1368)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- liver fibrosis, fibrosis resolution, hepatic stellate cells, hepatic stellate cell activation, extracellular matrix accumulation, liver cirrhosis, hepatocellular carcinoma, antifibrotic therapy, signaling pathways, therapeutic target, apoptosis
- MeSH terms
- Fibrosis, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Hepatic Stellate Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.